Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Further clinical data on dapagliflozin available

Oct. 22, 2012

EMA committee issues opinion on Qsiva

Oct. 19, 2012

Hyundai Pharmaceutical patents new 11-beta-HSD1 inhibitors

Oct. 19, 2012

FDA committee votes to recommend approval of Kynamro

Oct. 19, 2012

Studies support the use of tofogliflozin in patients with renal impairment

Oct. 19, 2012

Novel antidiabetic drug Subetta evaluated in animal model

Oct. 19, 2012

FDA advisory committee recommends approval of lomitapide for HoFH

Oct. 18, 2012

DiaMedica reports preclinical results from DM-199 study

Oct. 17, 2012

Resverlogix begins phase II trial of RVX-208 in patients with prediabetes

Oct. 17, 2012

Scientists at Wellstat Therapeutics disclose novel URAT1 inhibitors

Oct. 17, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...